EXPLORE!

CNS Update: Pregabalin in Patients with Central Post-Stroke Neuropathic Pain

  1246 Views

eMediNexus    27 February 2023

Stroke patients frequently encounter central post-stroke neuropathic pain. A recent study analyzed the rate of pain reduction in central post-stroke neuropathic pain with pregabalin therapy. 

 

It collected data prospectively on 36 patients with central post-stroke neuropathic pain, who received Pregabalin 75 mg/day and measured Pain levels using a visual analogue scale at the start of therapy, and at weeks 2, 4, 8, and 12 of treatment. 

 

It then conducted a survival analysis to determine the rate of pain reduction (time vs. pain reduction >50%) using the Kaplan-Meier survival curve and the log-rank test. 

 

The results showed that Pregabalin could significantly reduce central post-stroke neuropathic pain in 69.7% of patients after 12 weeks of treatment. Pregabalin showed no significant difference in the rate of pain reduction between:

  • men and women, 
  • the age groups <55 years and >55 years,  
  • the onset of pain <12 months and >12 months, 
  • <2 episodes of disease and >2 episodes of disease,  
  • <2 medications used and >2 medications used. 

 

Thus, Pregabalin can significantly reduce central post-stroke neuropathic pain in 69.7% of patients after 12 weeks of treatment, irrespective of gender, age, pain onset, history of diseases, or history of the medications.

 

Rahajeng B, Dwiprahasto I, Ikawati Z, Andayani TM. Kaplan-Meier Survival Curve Analysis: Pregabalin Therapy in Patients with Central Post-Stroke Neuropathic Pain. International Journal of Pharmaceutical Research. 2021;13(1): 2805-2814.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.